Avacta Group Announces Board Changes Amid Strategic Transition

An announcement from Avacta Group plc ( (GB:AVCT) ) is now available.

Avacta Group plc announced the retirement of Dr. Trevor Nicholls from its Board, effective April 30, 2025. Mark Goldberg will assume the role of Chair of the Remuneration Committee. As Avacta transitions to a pure-play biotechnology company, it is seeking to appoint a new independent non-executive director with international commercial expertise, signaling a strategic shift in its operations.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company focused on developing targeted oncology drugs. It utilizes its proprietary pre|CISION® platform, which is designed to deliver potent cancer therapies specifically to tumor sites while minimizing impact on healthy tissues. The company’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates, offering advantages over traditional treatments.

YTD Price Performance: -37.00%

Average Trading Volume: 1,861,978

Technical Sentiment Signal: Buy

Current Market Cap: £120.8M

For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.